Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban)

  Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS®

Business Wire

PRINCETON, N.J. & NEW YORK -- December 28, 2012

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today
announced that the U.S. Food and Drug Administration (FDA) has approved
ELIQUIS^® (apixaban).

Please see full Prescribing Information including BOXED WARNING and Medication
Guide available at

Bristol-Myers Squibb and Pfizer will provide additional information on the FDA
approval of Eliquis in a separate press release, to be issued next week.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
discover, develop and deliver innovative medicines that help patients prevail
over serious diseases. For more information, please visit
or follow us on Twitter at

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and
well-being at every stage of life. We strive to set the standard for quality,
safety and value in the discovery, development and manufacturing of medicines
for people and animals. Our diversified global health care portfolio includes
human and animal biologic and small molecule medicines and vaccines, as well
as many of the world’s best-known consumer products. Every day, Pfizer
colleagues work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases of
our time. Consistent with our responsibility as the world’s leading
biopharmaceutical company, we also collaborate with health care providers,
governments and local communities to support and expand access to reliable,
affordable health care around the world. Formore than 150 years,Pfizer has
worked to makea difference for all who rely on us.


Bristol-Myers Squibb
Laura Hortas, 609-240-7025
Ranya Dajani, 609-252-5330
Ryan Asay, 609-252-5020
Pfizer Inc.
MacKay Jimeson, 212-733-2324
Suzanne Harnett, 212-733-8009
Press spacebar to pause and continue. Press esc to stop.